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Abstract The mechanisms operating in lymphocyte
recruitment and homing to liver are reviewed. A
literature review was performed on primary biliary
cirrhosis (PBC), progressive sclerosing cholangitis
(PSC), and homing mechanisms; a total of 130 papers
were selected for discussion. Available data suggest that
in addition to a specific role for CCL25 in PSC, the CC
chemokines CCL21 and CCL28 and the CXC chemo-
kines CXCL9 and CXCL10 are involved in the recruit-
ment of T lymphocytes into the portal tract in PBC and
PSC. Once entering the liver, lymphocytes localize to
bile duct and retain by the combinatorial or sequential
action of CXCL12, CXCL16, CX3CL1, and CCL28 and
possibly CXCL9 and CXCL10. The relative importance
of these chemokines in the recruitment or the retention of
lymphocytes around the bile ducts remains unclear. The
available data remain limited but underscore the impor-
tance of recruitment and homing.
Keywords Lymphocytehoming.Mucosaladdressincellular
adhesionmolecule-1/MAdCAM-1.Chemokines.
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Introduction
Primary biliary cirrhosis (PBC) and primary sclerosing
cholangitis (PSC) are chronic cholestatic liver diseases
characterized by progressive destruction of bile ducts.
Whereas PBC affects the small intrahepatic bile ducts,
PSC involves the intra- and/or extrahepatic bile ducts. PBC
is an organ-specific autoimmune disease with female
predominance, genetic predisposition, high titer serum
anti-mitochondrial autoantibodies, disease-specific antinu-
clear autoantibodies, frequent association with other auto-
immune diseases, and strong indications that the destruction
of small bile ducts is autoimmune-mediated [1]. PSC shares
many of these features including p-ANCA autoantibodies
in up to 80% of patients, genetic predisposition, and
association with other autoimmune diseases. In particular,
there is a link between inflammatory bowel disease (IBD),
with >70% of PSC patients having IBD, most frequently
ulcerative colitis, at some point during their lives. None-
theless, PSC differs from classical autoimmune diseases in
male rather than female predominance and is poorly
responsive to immunosuppressive treatment. In addition,
there is only circumstantial evidence that bile duct
destruction in PSC is an immune-mediated response to an
autoantigen [2, 3].
Both PBC and PSC are characterized by massive
infiltration of T cells into the portal tract, the infiltrate
consisting predominantly of T cells [4-7]. For reviews and
discussion on the immunobiology of PBC, including
generic mechanisms of autoimmunity, we refer to several
recent and key publications [8-22].
In PBC liver compared to peripheral blood, there is a
100-fold enrichment of CD4+ T cells and a 10-fold
enrichment of CD8+ T cells specific for the major PBC
autoantigen, strongly suggesting that both populations
participate in the bile duct injury seen in PBC [1]. In
keeping with a major role for cellular immune mechanisms
in PBC, there is type-1 cytokine predominance in serum
and liver of PBC patients [23, 24]. Very little is known
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the cytokine milieu in PSC liver, except that liver-
infiltrating lymphocytes (LIL) from PSC patients produce
significantly increased amounts of TNFα and IL-1β but
decreased levels of IFNγ [7].
According to the general paradigm, leukocyte extrava-
sation is a complex multistep process that begins with
“tethering” and rolling of blood-born leukocytes, i.e.,
reversible and transient interactions mediated mainly by
selectins. This slows down the immune cells sufficiently to
allow them to interact with chemokines presented by
endothelial cells. These can then increase the affinity and
avidity of leukocyte integrins for their endothelial adhesion
molecule receptors, thereby allowing firm adhesion to
occur. The adhesion molecules involved in firm attachment
frequently belong to the immunoglobulin superfamily,
which includes intercellular adhesion molecules (ICAM)-
1–5, vascular cell adhesion molecule 1 (VCAM-1), and
mucosal addressin cellular adhesion molecule 1 (MAd-
CAM-1). Firm adhesion is a prerequisite for subsequent
transendothelial migration into the tissue. Once lympho-
cytes have entered a specific tissue, they follow sequential
and combinatorial chemotactic gradients to their final
destination.
Chemokines play an essential role at every step of this
adhesion cascade and subsequent migration. They do so by
increasing the affinity and avidity of integrins for their
adhesion molecules, providing chemotactic signals for
transendothelial migration and the subsequent migration to
specific compartments within a tissue and by triggering
integrin activation required for the binding to adhesion and
cell-matrix molecules involved in tissue retention. They are
divided into four subfamilies (CC, CXC, C, and CX3C,
with CC and CXC chemokines representing the largest
group) based on the arrangement of the first two of four
conserved cysteine residues. They can be further subdi-
vided functionally into homeostatic and inflammatory
chemokines (see Table 1 for the nomenclature and receptor
usage of inflammatory cytokines). Inflammatory chemo-
kines are induced or upregulated during inflammation and
mediate leukocyte recruitment; homeostatic chemokines are
constitutively expressed and regulate navigation of leuko-
cyte precursors during hematopoiesis and of mature
lymphocytes in secondary lymphoid tissue [25]. Note,
however, that some chemokines (e.g., CCL21) do not
neatly fit into one of these categories.
There is increasing evidence that chemokines do not
establish soluble chemokine gradients at the luminal
endothelial surface but instead are immobilized via
attachment to specific glycosaminoglycans [26, 27].
Therefore, the production of specific glycosaminoglycans
by endothelial cells may represent mechanisms to provide
tissue-specific recruitment signals [26, 27]. In addition,
although endothelial cells can produce many chemokines,
themselves, they are also able to take up, transcytose and
then present chemokines produced by surrounding cells
[27, 28].
Chemokines exert their effects through binding to seven-
membrane-spanning G-protein coupled receptors expressed
on leukocyte and lymphocyte subsets. Frequently, a certain
chemokine can bind to several different receptors; con-
versely, a receptor can be shared by several chemokines.
There is extensive cross-talk between chemokines on
numerous levels, e.g., through downregulation of shared
receptors [29], enhancing the surface density of unrelated
receptors [30] or through blocking of signaling events
downstream from receptor activation [31].
Naïve lymphocytes recirculate between blood and
peripheral lymph nodes. During this stage, they express
L-selectin and CCR7, which allow them to enter lymph
nodes which express the L-selectin ligand peripheral lymph
node addressin (PNad) and the CCR7 ligands, CCL19 and
CCL21. Once lymphocytes encounter their cognate antigen,
they generally downregulate CCR7 and L-selectin expres-
sion and instead acquire a different set of adhesion
receptors that allow them to be recruited to sites of
inflammation and/or to “home,” i.e., to preferentially return
to the tissue in which they were originally activated.
Recruitment and homing to certain tissues has been shown
to involve the recognition of specific “addressins,” i.e.,
tissue-specific ligands expressed by vascular endothelial
cells, by homing receptors expressed on the lymphocyte. A
further level of specificity is provided by chemokine
receptor pairings. For example, homing to the gut is
mediated by α4β7 integrin on lymphocytes binding to
mucosal MAdCAM-1. The chemokine CCL25, which is
capable of activating α4β7, is expressed preferentially in
the small intestine, where it interacts with lymphocytes
expressing its cognate receptor CCR9. Skin homing
involves interactions between cutaneous lymphocyte anti-
gen with E-selectin and CCL17 with CCR4. No specific
addressin has been identified for the liver.
A unique feature of the liver is its dual blood supply,
with arterial blood entering via the hepatic arteries and
venous blood coming from the gut via the portal veins.
Hepatic arterioles and portal venules transport arterial and
venous blood into the sinusoids, which then take it through
the lobule to the central vein. Lymphocytes can enter the
liver at several sites, the most important probably being the
portal vessels and the sinusoids. Portal veins constitutively
express low levels of ICAM-1 and occasionally ICAM-2
and VCAM-1 [32-35]. E-selectin is generally not detectable
[32, 36], whereas P-selectin may be weakly expressed on
some portal vein endothelia [32]. Lymphocyte extravasa-
tion at this site is thought to proceed according to the
general paradigm.
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[32, 37] and ICAM-2 [32], whereas levels of VCAM-1 and
E-selectin are minimal or undetectable [32, 36]. Note,
however, that constitutive expression of E-selectin has been
reported on cultured hepatic sinusoidal endothelial cells
(HSEC) [38]. Lymphocyte recruitment in the sinusoids does
not involve the classical tethering and rolling step in
cultured human [39] or mice HSEC [40]. Instead, the vast
majority of lymphocytes immediately arrest. This is thought
to be due to the low to undetectable levels of sinusoidal
selectin expression, which seems to be dispensable in the
low-shear environment of the sinusoids. There are indica-
tions that vascular adhesion protein 1 (VAP-1) plays a
particularly important role in lymphocyte extravasation in
the sinusoids.
Adhesion molecules in PBC and PSC
VAP-1
Unlike most other adhesion molecules, VAP-1 does not
belong to the selectin, integrin, or immunoglobulin super
families but is a syaloglycoprotein and copper-containing
semicarbazide-sensitive amine oxidase that exists in both
membrane-bound and soluble forms [41]. It mediates sialic-
acid-dependent adhesion of lymphocytes to peripheral
lymph node high endothelial venules (HEV) [42] and
promotes shear-dependent lymphocyte adhesion to, and
transmigration across, hepatic sinusoidal endothelium in
vitro [39, 43, 44]. Both its adhesive function and enzyme
activity contribute to these processes [38, 39, 45]. In
addition, VAP-1 has been shown to activate hepatic
endothelial cells, resulting in the upregulation of E-
selectin, P-selectin, ICAM-1 transcription and translation,
and enhanced production of CXCL8 (IL-8), thereby
increasing lymphocyte adhesion [46, 47]. The lymphocyte
ligand of VAP-1 has not been identified. From available
data, it also remains unclear at which step of the adhesion
cascade VAP-1 comes into play. Studies with isolated
hepatic sinusoidal endothelial cells suggest that it mediates
firm adhesion but does not affect lymphocyte rolling [47],
whereas the results obtained with liver sections point to a
role in the early tethering interactions [43, 44]. Recent data
obtained with VAP-1 expressing rabbit heart endothelial
cells suggest that VAP-1 functions after the initial tethering
step [45]. VAP-1 can use primary amine groups on the
surface of lymphocytes as a substrate. During the reaction,
a transient covalent bond is formed between the endothelial
VAP-1 and the lymphocyte. This comes into play after the
initial tethering and reduces the rolling velocity, thereby
providing time for the chemokine-mediated integrin activa-
tion that is a prerequisite for firm adhesion.
In humans, VAP-1 is constitutively expressed in endothe-
lial cells of several organs and tissues, with the greatest
abundance found in high endothelial venules of peripheral
lymph nodes. Hepatic vascular and sinusoidal endothelium,
but not bile ducts or hepatocytes, also express low
constitutive levels of this protein [43, 44]. Inflammation or
inflammatory mediators can induce VAP-1 in a tissue-
specific manner [48, 49]. However, data from a very limited
number of patients with acute liver allograft rejection or PBC
Table 1 Chemokines, their official and common names, and their receptors
Official
nomenclature
Common name Abbreviation Receptor
CCL2 Monocyte chemoattractant protein-1 MCP-1 CCR2, CCR4, CCR9
CCL3 Macrophage inflammatory protein-1α MIP-1α CCR1, CCR5
CCL4 Macrophage inflammatory protein-1β MIP-1β CCR5, CCR9
CCL5 Regulated upon activation normal T l CCR1, CCR3, CCR5, CCR9
CCL20 Macrophage inflammatory protein-3α,
Liver and activation regulated chemokine
MIP-3α,
LARC CCR6
CCL21 Secondary lymphoid chemokine SLC CCR7
CCL25 Thymus-expressed chemokine TECK CCR9
CCL28 CCR10
CXCL9 Monokine induced by IFNγ MIG CXCR3
CXCL10 IP-10 CXCR3
CXCL11 IFN-inducible T cell a chemoattractant I-TAC CXCR3
CXCL12 Stromal (cell)-derived factor-1 SDF-1 CXCR4
CXCL16 CXCR6
CX3CL1 Fractalkine CX3CR1
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sion in portal and sinusoidal endothelium or induce it in
other cell types since both the pattern and intensity of VAP-1
immunoreactivity were the same in normal and diseased
livers [43] (see also Table 2). Consistent with these
observations, cultured HSEC were found to constitutively
produce low levels of VAP-1, which were not enhanced by
incubation with TNFα,I L - 1 β,I F N γ,b i l ea c i d s ,o rL P S[ 39].
All of these agents (with the exception of bile acids which
were not tested) can enhance VAP-1 expression in certain
other tissues in an organ- and cell type-specific manner [49].
Of particular note, there are indications that VAP-1 in
human peripheral lymph nodes has marked lymphocyte
subset selectivity, mediating shear-resistant adhesion of
CD8+ T cells and NK cells but binding CD4+ T cells
poorly [42, 50]. Whether VAP-1 on hepatic endothelium is
equally subset-specific has not been investigated. Further-
more, in mice, VAP-1 selectively mediates the hepatic
recruitment of Th2 cells, whereas Th1 cells used α4β1
integrin [51]. However, in vitro generated Th1 and Th2
cells, as used in this study, frequently do not adequately
reproduce the behavior of their in vivo counterparts [52,
53]. In view of the importance of Th1 and CD8+ T cells in
PBC and possibly PSC, it would be interesting to establish
the relevance of these findings and also their pertinence to
human liver.
ICAM-1 and VCAM-1
In normal human liver, there is constitutive, though weak
expression of ICAM-1 on sinusoidal endothelium, still
weaker or even undetectable levels have been reported on
portal endothelium [32-34, 37], and no staining has been
detected on bile ducts. Immunoreactivity for VCAM-1, if at
all detectable, is generally confined to the portal endothe-
lium in normal liver [32-34, 54]. Note, however, that in
primary culture, both human biliary epithelial cells (BEC)
and HSEC constitutively express low levels of ICAM-1,
whereas VCAM-1 is not always detectable [39, 55]. As is
seen in numerous other endothelial and epithelial cell types,
expression of ICAM-1 is enhanced and that of VCAM-1
induced or upregulated by incubation with inflammatory
cytokines (TNFα or IL-1β) or IFNγ.
In PBC and PSC, ICAM-1 and VCAM-1 are induced or
upregulated on portal and sinusoidal endothelium [34, 35,
37, 56] (see also Table 2). This upregulation of ICAM-1
and VCAM-1 is not only applied to PBC and PSC but is
also seen in other inflammatory liver diseases, including
acute and chronic rejection and viral hepatitis [32, 33, 57],
although there are some indications that the pattern is
somewhat disease-specific [58]. However, upregulation of
ICAM-1 expression on bile ducts seems to be quite specific
for PBC, PSC, and other liver diseases in which bile ducts
are the major targets of immune-mediated destruction [32,
34, 35, 59, 60]. VCAM-1 is only very occasionally detected
on bile ducts of PBC and PSC patients [34, 35]. Note,
however, that immunoreactivity for ICAM-1 on bile ducts
and ductules is detected in some but not all patients with
PSC and PBC [34, 35, 37, 61]. Both its presence and its
distribution seem to depend on the disease stage since it is
seen almost exclusively in more advanced disease [35].
This suggests that ICAM-1 induction or upregulation is a
consequence rather than a cause of bile duct inflammation.
Lymphocytes expressing the ICAM-1 ligand, LFA-1, are
seen only occasionally in normal liver, and their frequency
is greatly increased in various liver diseases [33, 34, 58].
Unlike hepatocellular liver diseases, LFA-1+ T cells are
found mostly around damaged bile ducts in the vicinity of
ICAM-1-expressing BEC [37, 61]. This indicates that
upregulation of biliary ICAM-1 can result in enhanced
lymphocyte recruitment to bile ducts.
MAdCAM-1 and the aberrant homing of mucosal
lymphocytes to PSC liver
There is a strong link between PSC and IBD, and certain
molecules involved in lymphocyte recruitment are shared
between the gut and the liver. This is thought to be part of
an enterohepatic lymphocyte recirculation that allows for
immune surveillance across both liver and gut, which
encounter some of the same antigens due to their
connection via the portal circulation. This prompted Grant
et al. [62] to formulate the hypothesis that PSC is mediated
by long-lived memory T cells that were originally activated
in the gut and are recruited to the liver due to aberrant
inflammation-induced expression of adhesion molecules
Adhesion molecule Portal vein Sinusoidal EC Bile ducts
normal PBC PSC Normal PBC PSC Normal PBC PSC
ICAM-1 −/(+) ++ ++ + ++ ++ −− /+ −/+
VCAM-1 −/(+) ++ ++ ++ ++ −− /(+) −/(+)
VAP-1 + + + + + + −− −
MAdCAM-1 − ++− ++−− −
Table 2 Changes in adhesion
molecule expression in PBC and
PSC
“−/(+)” negative or occasionally
weakly positive. “−/+” negative
in some, positive in other
patients
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these cells become activated in the liver by cross-reactive
self-antigens in the liver or by gut antigens that have
entered the liver via the portal vein, the inflammatory
response may become exaggerated and, if prolonged, result
in chronic inflammation.
Several lines of evidence support this hypothesis. Under
normal conditions, the mucosal vessels of the gut are
essentially the only site of MAdCAM-1 expression in
humans [63]. However, this adhesion molecule, while not
detected in normal liver, can be expressed by hepatic
endothelium of patients with chronic inflammatory liver
disease [64, 65]. Discussions of the role that aberrant
homing of mucosal lymphocytes plays in the pathogenesis
of the hepatic complications of IBD underscores the
importance of MAdCAM-1 expression in inflammatory
liver diseases “associated with IBD” [62, 66, 67]. However,
this statement is somewhat incomplete. In one of the only
two existing studies on the expression of this adhesion
molecule in human liver diseases, Hillan et al. [65] detected
MAdCAM-1 expression in association with portal tract
inflammation, whether due to hepatitis B or C, PBC, or
PSC. In particular, portal vessels and lymphoid aggregates
stained positive, and this is similar to the results reported by
Grant et al. [64], who detected some additional staining of
the sinusoids. However, the proportions of specimens
positive for MAdCAM-1 differed between the studies.
Grant et al. [64] reported that the majority of specimens
from PSC and autoimmune hepatitis (AIH) patients (88%
and 70%), but only 64% of PBC and 14% of chronic
rejection specimens, showed immunoreactivity. In contrast,
71% of needle biopsy samples from PBC patients, but only
20% of specimens of PSC patients, were positive for
MAdCAM-1 in the investigation by Hillan et al. [65].
However, in that study, all explanted liver samples from
PBC and PSC patients demonstrated immunoreactivity for
this adhesion molecule. This may simply reflect the focal
nature of MAdCAM-1 expression, limiting the detection in
small biopsy samples. It could indicate, however, that
MAdCAM-1 is increasingly upregulated with disease
progression and that could suggest that expression of this
adhesion molecule is a consequence rather than a cause of
inflammation. In order to clarify the true extent of
MAdCAM-1 expression and its relation to the disease
stages in PSC and PBC, further investigations are clearly
needed.
In a study of nine PSC patients, the MAdCAM-1 ligand,
α4β7 integrin, was expressed on LIL from seven with 10%
and 50% of infiltrating lymphocytes in portal tracts staining
positive for α4β7 expression compared to <10% of
lymphocytes in PBC samples [5] .G r a n te ta l .[ 64],
themselves, reported that only ∼10% of LIL in PSC
expressed α4β7 compared to ∼40% of PBL from the same
patients. However, PSC liver contains a higher proportion
of αEβ7+ T cells compared to peripheral blood, and α4β7
T cells have been reported to differentiate within tissue into
αEβ7+ cells. Unfortunately, LIL from PBC or AIH patients
were not analyzed by flow cytometry, even though
immunohistochemistry reveals that a proportion of intra-
hepatic lymphocytes in all liver diseases studied were
positive for α4β7. Further studies are called for in order to
resolve the question whether α4β7 expression characterizes
mainly LIL in PSC or pertains to essentially all liver
diseases.
Chemokines in PBC and PSC
Chemokines that can trigger α4β7-mediated binding
to MAdCAM-1
CCL25 Interactions between the gut-specific chemokine
CCL25 with its receptor CCR9 results in activation of the
α4β7 integrin, thereby allowing firm adhesion of lympho-
cytes to MAdCAM-1 [68]. Note, however, that it did not
trigger the shape changes associated with motility and
transendothelial migration. In addition to the MAdCAM-
1–α4β7 pairing, this provides another level of specificity in
the gut homing of lymphocytes. Analysis of CCL25 and
CCR9 expression in various liver diseases indicates that
CCL25 immunoreactivity, detected mainly on sinusoidal
endothelium in areas of interface hepatitis, was highly
specific for PSC since it was not seen in PBC and other
inflammatory liver diseases [69] (see also Table 3). CCR9
was detected on 20% of LIL in PSC where it was
frequently co-expressed with α4β7 while <2% of LIL were
CCR9 positive in other liver diseases. Although these
results await independent confirmation, they strongly
suggest that the MAdCAM-1/α4β7/CCL25/CCR9 axis
plays a specific role in the pathogenesis of PSC but not in
PBC and other inflammatory liver diseases. They also
provide further support for the hypothesis that PSC
involves aberrant homing of mucosal lymphocytes to the
liver. Note, however, that CCR9+ lymphocytes are found
almost exclusively in the small intestine, whereas few are
detected in the colon [70]. Similarly, CCL25 is specifically
expressed in the small intestine and not in the colon.
Therefore, one would expect PSC to be associated mainly
with Crohn′s disease, which affects the entire gut, but not
with ulcerative colitis, affecting only the colon. For as yet
unknown reasons, the opposite is the case. However, it is
interesting that the ulcerative colitis associated with PSC
has a unique phenotype in which there is ileal involvement
and rectal sparing [71]. An understanding of the factors that
induce the expression of CCL25 in liver and intestine may
shed some light on this paradox but remains elusive.
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rin and CCL25/CCR9 are specifically involved in the
recruitment of lymphocytes to liver diseases associated
with IBD, the question then arises as to what, if any,
function MAdCAM-1 expression has in PBC and other
hepatic diseases. In this context, it is interesting to note that
not only CCL25 but also CCL21, CCL28, and CXCL12 are
capable of triggering α4β7-mediated adhesion of human
PBL to MAdCAM-1 under shear stress in vitro [68, 72, 73].
Therefore, whether these chemokines play a role in the
recruitment of T lymphocytes to PBC liver via
MAdCAM-1 will depend on the actual number of
α4β7-positive lymphocytes that enter the liver. CCL21
is a chemokine usually expressed on HEV in peripheral
lymph nodes and Peyer′s patches, and its ability to
activate the α4β7 integrin-mediated adhesion of lym-
phocytes to MAdCAM-1 [68, 72] plays an important role
in the recruitment of naïve lymphocytes to Peyer′s
patches. In addition, CCL21 can also trigger the shape
changes that precede transendothelial migration and can
activate α4β1 integrin-mediated lymphocyte binding to
VCAM-1 under fluid flow [68].
A characteristic of PSC, PBC, and a variety not only
of other autoimmune disease but also of chronic
hepatitis C (CHC) is the presence of lymphocyte
aggregates in the target organ. These organize into
lymphoid follicles that contain HEV expressing either
PNAd or MAdCAM-1 [64]. In mice, ectopic expression
of CCL21 results in lymphoid neogenesis [74, 75]; the
presence of CCL21 is sufficient to trigger integrin-
dependent adhesion of naïve lymphocytes to nonlym-
phoid tissue and to induce their extravasation [76]. In
human autoimmune diseases such as ulcerative colitis or
rheumatoid arthritis, the lymphoid neogenesis is associ-
ated with expression of CCL21 mRNA in endothelial
cells, including the HEV within the lymphoid follicles as
well as blood vessels outside these organized lymphoid
structures [76].
CCL21 is restricted to a few small lymphatic vessels in
normal liver but is expressed in portal tracts in PSC and
PBC, particularly in lymphoid aggregates [77]. The
strongest immunoreactivity is seen on vascular endothelium
of vessels exhibiting the morphology of HEV. Lymphoid
aggregates in PBC; PSC and other liver diseases also
demonstrated MAdCAM-1 immunoreactivity, and some
vessels with HEV morphology within these aggregates are
occasionally positive for MAdCAM-1 staining [64, 65].
This suggests a functional role for CCL21 in the recruit-
ment of CCR7+ lymphocytes to the lymphoid aggregates
within PBC and PSC portal tracts. CCR7, the receptor for
CCL21, was expressed on a significantly higher percentage
of PBL (76% vs. 50%) and intrahepatic T cells (20% vs.
9%) from PSC and PBC patients compared to healthy
controls [77]. Of note, a high proportion of LIL in PSC
were CD45RA+, and not all could be characterized as
primed T cells that had reverted to a CD45RA+ phenotype.
This suggests that CCL21 plays a role in the recruitment of
naïve T cells to the liver, which would be consistent with
the observation that murine CCL21 can recruit naïve T
lymphocytes to nonlymphoid tissues [76]. Together, these
results support the hypothesis that lymphoid neogenesis
provides an environment for interactions between immune
cells and antigen-presenting cells within the peripheral
tissue that represents the antigen source [75] and, therefore,
a site where autoreactive naïve T cells may be primed
directly at the site of inflammation [76].
CCL28 Like CCL25 and CCL21, CCL28 can trigger
α4β7-mediated adhesion of human PBL to MAdCAM-1
as well as α4β1-mediated binding to VCAM-1 under shear
stress in vitro [68, 72, 73]. It also induces transwell
chemotaxis of PBL and LIL [78]. Furthermore, it can
mediate static adhesion of LIL from PSC, PBC, or alcoholic
liver disease (ALD) to immobilized MAdCAM-1 via α4β7
and to VCAM-1 via α4β1[ 78]. Both of these adhesion
molecules are expressed in the portal endothelium in PBC
Chemokine Portal vein Sinusoidal EC Bile ducts
normal PBC PSC normal PBC PSC Normal PBC PSC
IP-10 − + (?) ND −/+ ND ND − +N D
MIG −/+ + (?) ND −/+ ND ND − +N D
ITAC − ND ND + ND ND ND ND ND
CCL21
CCL25 −− − −− ++ −− −
CCL28 − ++ −− − − ++ ++
CXCL12 (SDF-1) −− − −− − ++ + + +
CXCL16 + + + + + + + ++ ++
CX3CL1 (fractalkine) + + + −− − (+) ++ (+)
Table 3 Changes in chemokine
expression in PBC and PSC
ND not determined; “−”
negative; “(+)” faint; “−/+”
nondetectable in some, weakly
positive in others; “+” clearly
detectable; “++” strong staining
314 Semin Immunopathol (2009) 31:309–322and PSC liver, whereas bile ducts never express
MAdCAM-1 and are only occasionally positive for
VCAM-1 in PBC patients [34, 35, 64, 65].
CCL28 is not detected in normal liver, but intense
staining is seen in livers of patients with PSC, PBC, or
ALD, not only on injured bile ducts but also on portal
endothelium and on reactive bile ductules [78]. Primary
human cholangiocytes can be induced to express CCL28
mRNA and protein by incubation with IL-1β or LPS. The
CCL28 receptor, CCR10, is expressed on almost 17% of
liver-infiltrating CD3+ Tcells in inflamed liver but only 6%
in healthy control liver, with the vast majority of CCR10+
cells being CD4+ T cells. Since MAdCAM-1 is not, and
VCAM-1 only occasionally, detected on bile ducts, the
main function of CCL28 expression in bile ducts may not
be in the extravasation of lymphocytes but in their
localization to bile ducts. Since binding to fibronectin is
also mediated by α4β1 integrin, CCL28 may also play a
role in the attachment of lymphocytes to this matrix
molecule and thereby enhance their tissue retention.
Of note, Foxp3 mRNA is preferentially contained in the
CCR10+ T cell population, indicating that this T cell
subset includes natural regulatory T cells. A decreased
frequency of Tregs has been reported from the liver and
peripheral blood of PBC patients [79, 80], although
i n c r e a s e dn u m b e r sw e r ef o u n db yo t h e r s[ 81]. It is
possible that this decrease is due to reduced expression
of CCR10 or other chemokine receptors that have been
implicated in the recruitment of Tregs, such as CCR8 [82]
or CCR5 [83]. However, first-degree relatives of PBC
patients also have a decreased frequency of Tregs in
peripheral blood [79], suggesting that there is a genetic
defect in the production of this lymphocyte subset rather
than a defect in their homing to the liver.
CXCL12 CXCL12, also called stromal (cell)-derived factor
1 (SDF-1), is a chemokine that induces its effects via
interaction with its specific receptor CXCR4. These effects
include enhancing both the initial tethering of lymphocytes
and their subsequent firm α4β1 integrin-mediated adhesion
to VCAM-1 on endothelial cells under fluid flow [68, 84].
In addition, CXCL12 is capable of triggering α4β7-
mediated binding of PBL or CD4+ T cells to MAdCAM-
1 and fibronectin under shear stress [68, 73]. Furthermore,
SDF-1 stimulates the chemotaxis of T cells, NKT cells, and
NK cells isolated from the liver of HCV patients and
healthy controls [85] and the transendothelial migration of
naïve and memory CD4+ and CD8+ T cells [86]. In normal
liver, SDF-1 is expressed exclusively on bile ducts in portal
tracts [87, 88]. Immunoreactivity largely remains confined
to the bile duct but is greatly enhanced not only in PBC and
PSC liver [69, 88] but also in the liver of patients with AIH,
CHC, or acute or chronic liver allograft rejection [85, 87,
88]. Interlobular and septal bile ducts show the strongest
immunoreactivity, but reactive bile ductules are also
positive. Both normal and diseased liver contained SDF-1
mRNA, and transcript for this chemokine was detected in
laser-captured BEC, but not hepatocytes, from patients and
controls [88]. Although the frequency of CXCR4 positivity
was equally high in PBL and LIL, the latter exhibited
greater intensity of CXCR4 expression, with both CD3+ T
cells and CD19+ B cells showing higher expression levels
surrounding SDF-1 positive bile ducts [87, 88]. Hepatic
gene expression profiles using cDNA array analysis of PBC
and PSC liver specimens reveals that CXCR4 is among the
most strongly upregulated genes in PBC liver compared to
normal liver and even compared to PSC liver [89].
Conversely, expression of the SDF-1 gene is more
markedly enhanced in PSC than in PBC. The exclusive
expression of SDF-1 on bile ducts in human liver indicates
that this chemokine does not have a role in the recruitment
of CXCR4+ lymphocytes to liver. However, once lympho-
cytes have entered the portal tract; SDF-1 functions in
attracting them to bile ducts. In addition, SDF-1 may have a
role in lymphocyte retention via its ability to augment their
adhesion to fibronectin [73, 85, 90]. The biliary basement
membrane demonstrates immunoreactive fibronectin in
80% of PBC patients but not in disease and normal control
livers [91]. It remains to be determined whether this
includes overexpression of the CS1 splice variant of
fibronectin, which contains the binding site for VLA-4
(α4β1 integrin). Overexpression of CS1-fibronectin has
been implicated in the retention of activated T cells in the
synovium of rheumatoid arthritis patients [92]. Note that
the interaction between lymphocytes and CS1-fibronectin is
usually mediated by α4β1 integrin, but α4β7 integrin may
also bind to this ligand [73]. Since SDF-1 can activate both
of these integrins, it would be capable of triggering
adhesion to fibronectin regardless of the integrin mediating
this interaction.
Other chemokines
CXCR3 ligands
As their common names indicate, the CXC chemokines
human monokine induced by IFN-γ (MIG, CXCL9), IFNγ-
inducible protein of 10 kDa (IP-10, CXCL10), and IFN-
inducible T cell α chemoattractant (I-TAC, CXCL11) are
induced by IFNγ. They trigger adhesion and transendothe-
lial migration under fluid flow as well as chemotaxis by
signaling through a common receptor, CXCR3 [55, 86, 93].
This receptor is expressed selectively on activated effector
or memory T cells [94], although more recent data suggest
that activation is not an absolute requirement [93].
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liver [55, 87, 95-97] or, when detected, are confined to
sinusoidal endothelium and occasional portal venules [87,
98-100]. Their upregulation in various inflammatory liver
diseases seems to follow chemokine- and disease-specific
patterns. In PBC liver samples, IP-10 and MIG were
induced in portal areas, including the damaged bile ducts
[96]. In chronic liver allograft rejection, which is also
characterized by progressive bile duct loss, IP-10 was
induced on bile ducts in portal tracts and was upregulated
on sinusoids [87]. MIG was not seen on any bile ducts but
was increased on sinusoidal endothelium; I-TAC was
induced on portal endothelium and some bile ducts but
was not detected on sinusoids. This contrasts with the
findings in CHC liver, where IP-10 and I-TAC are either
found to be upregulated almost exclusively on hepatocytes
[97, 99, 101] or exclusively on sinusoids [98, 102], whereas
MIG has been reported to be induced or enhanced
selectively on sinusoids [97, 98, 100]. A high frequency
of CXCR3 lymphocytes, predominantly CD4+ T cells, was
detected in PBC portal tracts, including damaged bile ducts
[96]. In addition, PBC patients exhibit a significantly higher
frequency of peripheral CXCR3+ CD4+ T cells compared
to healthy controls. Similar results have been reported from
patients with liver allograft rejection [87] and CHC patients
[55, 100, 101]. Note that increased CXCR3 expression on
infiltrating T cells is not confined to inflammatory diseases
of the liver but seems to be a general feature of
inflammation [103].
Together, these results suggest that expression of IP-10
in bile ducts may be characteristic of liver diseases where
bile ducts are specifically targeted, including PBC and
chronic liver allograft rejection; expression on hepatocytes
seems to be typical of certain stages of forms of CHC;
whereas induction or upregulation on sinusoidal cells is
seen in both chronic rejection and CHC, but not in PBC.
MIG also seems to participate in the recruitment of T cells
to the portal tract in PBC, whereas it is expressed only on
sinusoidal endothelium in chronic rejection and chronic
hepatitis C. The available data on I-TAC are limited but
suggest that this chemokine may be involved in the portal
inflammation seen in chronic rejection but may play a role
in the recruitment into the liver parenchyma via the
sinusoids in CHC.
Plasma levels of IP-10 and MIG were elevated not only
in PBC patients [96, 104] but also in their first degree
relatives compared to controls [96]. In PBC patients, levels
increased with advancing disease stage. Increased serum
concentrations of IP-10 are also seen in patients with AIH
[104], CHC [102, 105], and chronic hepatitis B [104],
although the latter is not a consistent finding [102].
Interestingly, in situ hybridization studies indicate that
IP-10 mRNA is expressed in hepatocytes of AIH, PBC, and
chronic hepatitis B and C patients but not in portal areas,
including the damaged bile ducts of PBC patients [104].
Similarly, others detected IP-10 transcripts mainly in
hepatocytes, particularly around areas of focal and piece-
meal necrosis in CHC patients [105]. On the other hand,
not only a human hepatocyte-derived cell line (Huh-7) [99]
but also cultured hepatic BEC [55, 106] and cultured
hepatic sinusoidal endothelial cells [55, 98] are capable of
producing all three CXCR3 ligands. IFNγ alone is
generally sufficient to induce the production of these
chemokines, whereas TNFα and IL-1β alone are often
ineffective but further augment IFNγ-induced secretion.
Relatively high levels of TNFα and IFNγ are present in
most inflammatory liver diseases, including PBC, CHC,
and liver allograft rejection. Therefore, other microenvir-
onmental factors must contribute to the disease-specific
expression patterns of the CXCR3 ligands. These could
include HCV infection itself since it has been shown that
transfection of HCV proteins or HCV RNA can stimulate
the transcription and protein synthesis of chemokines,
including IP-10 MIG and I-TAC [99, 107]. In PBC, LIL
may play a role in further enhancing the chemokine
production of BEC induced by certain other stimuli [106].
In addition, PBC LIL has been reported to exhibit enhanced
chemotaxis to IP-10 and other chemokines compared to
LIL from patients with viral hepatitis.
CXCL16 Another chemokine that might be involved in the
recruitment of lymphocytes to bile ducts is CXCL16,
constitutively expressed on bile ducts, hepatocytes, sinus-
oids, and to a lesser extent, on portal vessels [108].
Expression of this chemokine is upregulated on bile ducts
in liver tissue from PBC and PSC, but not CHC, patients,
whereas hepatocyte and sinusoid staining is enhanced in
CHC. This pattern recaptures the disease-specific distribu-
tion of CXCR3 ligands. In matched samples, significantly
higher percentages of LIL than PBL were positive for the
CXCL16 receptor, CXCR6, in liver donors as wells as
patients with end-stage CHC [108]. In cell culture,
cholangiocytes demonstrate stronger expression of
CXCL16 than hepatocytes and sinusoidal endothelial cells,
which were nonetheless also positive. This chemokine was
shown to enhance the adhesion of LIL and, to a lesser
degree, PBL to primary cholangiocytes under static
conditions, by activating α4β1i n t e g r i n( V L A - 4 )a n d
thereby increasing its ability to bind to VCAM-1. This
suggests that CXCL16 is important for the retention of
lymphocytes on bile duct epithelium either through
VCAM-1 or, since VCAM-1 is rarely detectable even in
PBC and PSC, possibly through the other α4β1 integrin
ligand, fibronectin. There are indications, though, that
CXCR6 may play a more general role in the targeting of
lymphocytes to, or their localization within, inflamed tissue
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found in inflamed liver but also in inflamed synovium of
psoriatic and rheumatoid arthritis [109]. Interestingly,
CXCR6 is preferentially expressed on type 1 (IFNγ-
expressing) CD4+ and CD8+ T cells, particularly by highly
differentiated effector Th1 cells and CD56+ granzyme A-
expressing effector CD8+ cells. These are the cell types that
are implicated in the destruction of bile ducts in PBC.
Fractalkine Fractalkine (CX3CL1) is an unusual molecule
in that it (1) is the first and, to date, only member of the
CX3C subclass of chemokines, (2) exists in both
membrane-bound and soluble form, and (3) is both an
adhesion molecule and a chemokine. It consists of a
chemokine domain atop a mucin-like stalk connected to a
single transmembrane region and a short intracellular tail.
Fractalkine in its membrane-anchored state mediates leu-
kocyte adhesion in an integrin-independent manner under
static and flow conditions [110, 111]. There are indications
that as in the interactions between other adhesion molecules
and their lymphocyte ligands, adhesion to fractalkine
requires a chemokine-mediated activation step [30]. In
contrast, soluble fractalkine acts as a true chemokine
capable of activating integrin ligands of other adhesion
molecules and fibronectin [112, 113] and of triggering
chemotaxis and transendothelial migration of certain mono-
cyte and lymphocyte subsets [114, 115].
Both adhesion and chemotaxis are mediated by inter-
actions between the chemokine domain of fractalkine with
the fractalkine receptor CX3CR1 [115], but only chemo-
taxis requires signaling through G proteins. The two forms
of fractalkine can show antagonistic activities [115-117].
CX3CR1 is expressed on monocytes, particularly CD16+
monocytes [118], but, above all, is a defining feature of
cytotoxic effector lymphocytes, as identified by their cell-
surface expression of CD57 and CD11b and intracellular
expression of granzyme B and perforin [117]. Included in
this group are terminally differentiated CD8+ T cells, NK
cells, γδ T cells, and a small subgroup of CD4+ T cells. Of
note, among CD4+ T cells, expression of CX3CR1 is
almost exclusively found on those lacking the costimula-
tory molecule CD28 [116, 119]; all CD28
– CD4+ T cells
are positive for CX3CR1 [119]. In addition, CX3CR1
expression and responsiveness to fractalkine is seen
predominantly in Th1 cells [120]. However, since CX3CR1
expression is confined to a small subset of CD4+ T cells,
the relevance of these findings remains to be established.
Immunohistochemistry revealed that CX3CL1 is
expressed on endothelial cells of small vessels in normal
liver and faint staining is also detected on some bile ducts
[121]. In liver biopsy samples from PBC patients, both the
signal intensity and the number of bile ducts showing
immunoreactivity is clearly increased, whereas neither the
pattern nor the intensity of staining is altered in PSC,
extrahepatic biliary obstruction, or CHC. From these data, it
would appear that upregulation of fractalkine on bile ducts
is specific to PBC. However, another group showed
fractalkine expression in inflammatory foci surrounding
regenerating nodules and also in bile-duct-like structures in
CHC [122]. Even stronger immunoreactivity was detected
in acute hepatitis due to acute HBV infection. In addition to
areas of inflammation and necrosis, there was intense
staining in regenerating epithelial cells within ductular
reactions.
The fractalkine receptor, CX3CR1, was expressed in a
few mononuclear cells in the portal tracts of normal livers
and expression was somewhat increased in other liver
diseases but was significantly higher in PBC patients,
where CX3CR1-positive lymphocytes were found predom-
inantly around damaged bile ducts [121]. Of note, CX3CR1
expression is rapidly downregulated on CD4+ T cells after
receptor engagement by fractalkine [119]. Consequently,
CX3CR1+ CD4+ T cells could not be detected in inflamed
colonic tissue from IBD patients, whereas CD28
–CD4+ T
cells, which all express this receptor, could be demonstrated
in inflamed mucosa. Therefore, CD28
− CD4+ T cells may
have escaped detection in PBC liver [121]. Note, however,
that the proportion of CD28
− CD4+ T lymphocytes is
significantly increased among PBL and intrahepatic T
lymphocytes of PBC patients compared to healthy controls
[123]. In particular, the intra-epithelial lymphocytes of
small bile ducts in PBC patients contained a much higher
number of CD28
− CD4+ T cells than seen in other liver
diseases or normal liver [124]. In contrast to CD28+ CD4+
T cells, CD28
− CD4+ T cells are cytotoxic, express high
levels of IFNγ, and are resistant to apoptosis. They are
strongly implicated in autoimmunity since their frequency
is significantly increased in a variety of autoimmune
diseases. The detection of fractalkine on BEC in PBC
together with the observation that this chemokine can act as
a chemoattractant for the CD28
− subset of CD4+ T cells
[117, 119] suggest an important role for fractalkine in the
recruitment of these cells to the bile ducts. In addition, it
has been shown that fractalkine can also function as a co-
stimulatory molecule and thereby increase granule exocy-
tosis and IFNγ production in CD28
− CD4+ T cells [116].
PBC patients exhibit a much higher precursor frequency
of CD4+ T cells that do not require co-stimulation for
proliferation and IFNγ production in response to the major
PBC antigen PDC-E2 163-176 [123]. Furthermore, some of
the co-stimulation-independent clones established from
these PDC-E2 163-176-specific CD4+ T cells lacked
CD28 expression. Nonetheless, this co-stimulatory function
of fractalkine may not play an important role in PBC, since
BECs, which are the major cell type expressing CX3CL1 in
PBC liver, have been shown not to act as antigen-
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T cells regardless of their co-stimulation requirement [125].
The detection of CX3CR1+ T cells in the liver of
patients with PBC and viral liver diseases suggests that
unlike CD28
− CD4+ Tcells, other T lymphocyte subsets do
not decrease their CX3CR1 expression after receptor
engagement. The group of cytotoxic effector lymphocytes
defined by expression of the fractalkine receptor CX3CR1
includes γδ T cells, 70% of which display this receptor on
their cell surface [117]. γδ T lymphocytes have been
implicated in various autoimmune diseases, and their
frequency is increased in peripheral blood and liver of
patients with PBC and PSC [126, 127]. It seems likely,
however, that CD8+ T cells, which are strongly implicated
in the bile duct damage seen in PBC and which also
frequently express CX3CR1, represent the major CX3CR1
+ population in PBC liver. The co-expression of fractalkine
and CX3CR1 on BEC, as seen in PBC [121], CHC, and
acute hepatitis due to HBV infection [122], suggests that
interactions between fractalkine and its receptor may also
be involved in tissue generation, particularly the recruit-
ment of epithelial cells and their arrangement into ductular
structures.
Macrophage inflammatory proteins and monocyte chemo-
attractant proteins Although originally named for their
ability to attract monocytes or macrophages, certain mem-
bers of the macrophage inflammatory protein (MIP) and
monocyte chemoattractant protein (MCP) families can also
induce chemotaxis and transendothelial migration of T cells,
in particular activated or memory CD4+ and CD8+ T
lymphocytes [86, 128]. In normal liver, portal vessels
constitutively express MIP-1α,M I P - 1 β, and MCP-1, sinus-
oids and bile ducts show no or only weak immunoreactivity,
and hepatocytes are always negative [57, 98, 129, 130].
There is little information on the role of these chemokines in
PBC and PSC. MCP-1 is not upregulated on BEC in PBC.
However, mononuclear leukocytes in the portal tracts
express MCP-1, MCP-2, and MCP-3, and this may in turn
recruit additional T cells into this area. Mainly, however,
MCP-2 and MCP-3 appear to be involved in the recruitment
of macrophages and the formation of granulomata.
Concluding remarks
The existing data on T lymphocyte recruitment to PSC and
PBC liver suggest the following scenario: inflammatory
signals in both PBC and PSC liver induce or enhance the
expression of adhesion molecules such as ICAM-1,
VCAM-1, and MAdCAM-1, whereas VAP-1 expression is
not altered. At the same time, a variety of chemokines are
also upregulated. In PSC, expression of CCL25, CCL21,
and CCL28 all are implicated in activating α4β7 integrins
and thereby enhancing lymphocyte binding to MAdCAM-
1. In addition, CCL21and CCL28 could promote adhesion
to VCAM-1 by activating α4β1 integrin. The same holds
true in PBC, except that CCL25 does not participate.
Several of these chemokines have also been shown to
enhance transendothelial migration. Data on other chemo-
kines are largely confined to PBC. They indicate that
induced or upregulated expression of MIG and IP-10 in
portal tracts may also contribute to enhanced lymphocyte
recruitment into PBC liver. Once lymphocytes have entered
the portal tract tissue, they are recruited to, and retained
around, the bile ducts by the combinatorial or sequential
action of CXCL12 (SDF-1), CXCL16, fractalkine
(CX3CL1), CCL28, and possibly MIG and IP-10. At this
point, the relative importance of each of these chemokines
in the recruitment or the retention of lymphocytes around
the bile ducts remains unclear. These limited data under-
score the complexity of lymphocyte recruitment and
homing to the liver. The data also suggest that there is no
liver addressin, but instead, liver homing is likely to require
complex combinations of adhesion molecule ligands and
chemokine receptors that provide not only entry into the
liver but also localization to specific liver compartments.
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